Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

ants totaled $980,000 for the year ended June 30, 2007 compared to zero in fiscal year 2006. In April 2007, the Company sold 3,043,478 shares of common stock and warrants and the Company recognized a change in the value of the warrants of $980,000 during the fourth quarter of fiscal year 2007 due to a decline in the Company's stock price during that time.

Bridge Financing

On September 12, 2007, the Company completed a $6.0 million debt and equity bridge financing under its effective shelf registration statement. In the financing, the Company issued $6.0 million in principal amount of 15% senior secured promissory notes due January 15, 2008 and 2,750,000 shares of common stock, which will be subject to certain trading restrictions until January 15, 2008. The Company expects to repay the indebtedness in October 2007 with proceeds from its planned registered public offering.

Reverse Stock Split

On September 12, 2007, the Company received stockholder approval for a reverse split of its outstanding common stock within a range of 1-for-5 to 1-for-7. On September 14, 2007, a committee of the Board approved the implementation of the reverse split at a ratio of 1-for-7. The reverse split will be come effective on Monday, September 17, 2007 and the Company's common stock will begin trading on the NASDAQ Capital Market on a post-split basis that day.

Upon effectiveness of the reverse split, every seven shares of common stock issued and outstanding will be automatically converted into one new share of common stock. Fractional shares that result from the split will not be issued and holders will be paid cash in lieu of fractional shares. The Company's common stock will trade under the symbol "NTIID" for 20 trading days to denote the reverse split. After that time, the symbol will revert to "NTII". Holders of record will receive instructions from American Stock Transfer & Trust Company, the Company's transfer agent, for how to surrender their pre-spl
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Inc. (OTC: MSEL) operating under its principal brand ... of visual communications and brand imaging solutions, was awarded " ... 9th Annual American Business Awards Ceremony, in recognition of its ... solid results, despite prevailing economic turbulence. The American ...
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... present data for its two first-in-class diabetes drugs, ... and its investigational diabetes drug candidates BYDUREON™ (exenatide ... at the 71st Scientific Sessions of the American ...
... 2011 Scientists Drs. Samuel and Elenore Bogoch of BioRadar ... in Replikin Counts of the EHEC lethal strains of E. ... of E. Coli have been studied in laboratories in Germany ... in the public databases. Replikins are subsequences of the genome ...
Cached Biology Technology:Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 2Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 3Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 4Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 6Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 7Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 8Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
... Scientists have completed the first study of microbes that ... the Gulf of Mexico, where conditions may resemble those ... was partially funded by the National Science Foundation (NSF), ... vents spew mud, oil, brine and gases that support ...
... Outreach efforts by the Translational Genomics Research Institute (TGen) ... the second year, TGen will help organize a cancer ... The 2nd annual Fort Defiance Cancer Awareness and Advocacy ... 8:30 a.m.-5 p.m. July 18 at the Navajo Nation ...
Cached Biology News:Global alliance of leading technological universities to address global societal issues 2Better living through chemistry 2Better living through chemistry 3TGen helps promote cancer awareness for vast Navajo Nation 2TGen helps promote cancer awareness for vast Navajo Nation 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: